Patents by Inventor Michael L. Whitfield

Michael L. Whitfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND AGENTS FOR TREATING, PREVENTING, DIAGNOSING, AND EVALUATING THERAPY FOR FIBROTIC, AUTOIMMUNE, AND INFLAMMATORY CONDITIONS
    Publication number: 20230374591
    Abstract: Novel methods of treating and/or preventing a fibrotic, autoimmune, and/or inflammatory disease or condition such as scleroderma, methods of diagnosing a fibrotic, autoimmune, and/or inflammatory disease or condition such as scleroderma and methods for predicting whether a therapy for a fibrotic, autoimmune, and/or inflammatory disease or condition such as scleroderma is effective are provided which involve detecting and/or modulating the expression of function of specific genes correlated to a fibrotic, autoimmune, and/or inflammatory disease prognosis. Also, agents and compositions containing for treating or preventing a fibrotic, autoimmune, and/or inflammatory disease or condition such as scleroderma and kits for detecting genes associated with a fibrotic, autoimmune, and/or inflammatory disease or condition such as scleroderma are provided.
    Type: Application
    Filed: October 7, 2021
    Publication date: November 23, 2023
    Inventors: Yue WANG, Michael L. WHITFIELD
  • GENE EXPRESSION SIGNATURE IN SKIN PREDICTS RESPONSE TO MYCOPHENOLATE MOFETIL
    Publication number: 20140066324
    Abstract: Described herein are methods and compositions for identifying patients with SSc or scleroderma who are responders to MMF treatment.
    Type: Application
    Filed: February 28, 2012
    Publication date: March 6, 2014
    Applicants: NORTHWESTERN UNIVERSITY, TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Michael L. Whitfield, Monique Hinchcliff, Chiang-Ching Huang
  • MOLECULAR SIGNATURES FOR DIAGNOSING SCLERODERMA
    Publication number: 20110190156
    Abstract: The present invention features methods for classifying, determining severity, and predicting clinical endpoints of scleroderma based upon the expression of selected biomarker genes.
    Type: Application
    Filed: July 15, 2009
    Publication date: August 4, 2011
    Applicant: Trustees of Dartmouth College
    Inventors: Michael L. Whitfield, Jennifer L. Sargent, Sarah A. Pendergrass, Ausra Milano